Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

COMPASS Psilocybin Depression Data Excite Despite Safety Issues

Executive Summary

The speed and efficacy of psilocybin candidate COMP360 in treatment-resistant depression in a Phase II study could outweigh the major safety events also seen.

You may also be interested in...



More De-Risking Required Before Pharma Dives Into Psychedelics

One of the best-attended sessions at the BIO meeting in San Diego saw psychedelics specialists weighing up the sector's chances of breaking taboos and getting to market.

Psychiatric Disorders Markets: Depression, Bipolar Disorder And Schizophrenia

PODCAST: Datamonitor Healthcare analysts explore the three key psychiatric disorder markets from current market leaders to promising pipeline candidates and novel mechanisms.

Cybin CEO: Big Pharma Can No Longer Sit On The Sidelines In Psychedelics

Podcast: Doug Drysdale, CEO of Cybin, tells Scrip about the controversial history of psychedelics and their potential role in addressing mental health disorders. The CEO also weighs in on consolidation in the psychedelic sector, which is currently dominated by biotech, and claims big pharma can no longer sit on the sidelines.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC145383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel